SavedAdd your journal

Journals / Retina-Vitreus / 2017 / Cilt: 26 - Sayı: 2

Comparison of The Effi ciency of Intravitreal Dexamethasone Implant and Ranibizumab in The Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion: 6 Months Results

Retina Ven Dal Tıkanıklığına Bağlı Makula Ödemi Tedavisinde İntravitreal Deksametazon İmplant ve Ranibizumab Etkinliğinin Karşılaştırılması: 6 Aylık Sonuçlar

Esra KUMRAL TÜRKSEVEN
Nursal Melda YENEREL
Elvan Alper ŞENGÜL
Serhat İMAMOĞLU
Nimet Yeşim ERÇALIK
Mehmet Şahin SEVİM
Handan BARDAK
Pages
127–132
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, at month 6, ranibizumab appeared to have a greater effect on central macular thickness reduction compared to intravitreal dexamethasone implant.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To compare the effi ciency of intravitreal dexamethasone implant and ranibizumab in the treatment of macular edema secondary to branch retinal vein occlusion at month 6.Methods: Sixty one eyes of 61 patients with macular edema secondary to branch retinal vein occlusion were evaluated retrospectively.
📊
Key Findings & Data:Twenty-nine patients (group 1) received 0.7 mg single dose intravitreal dexamethasone implant and 32 patients (group 2) received 0.5 mg PRN ranibizumab injection.
💡
Conclusion & Impact:However, at month 6, ranibizumab appeared to have a greater effect on central macular thickness reduction compared to intravitreal dexamethasone implant.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To compare the effi ciency of intravitreal dexamethasone implant and ranibizumab in the treatment of macular edema secondary to branch retinal vein occlusion at month 6.Methods: Sixty one eyes of 61 patients with macular edema secondary to branch retinal vein occlusion were evaluated retrospectively. Twenty-nine patients (group 1) received 0.7 mg single dose intravitreal dexamethasone implant and 32 patients (group 2) received 0.5 mg PRN ranibizumab injection. Best corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded at baseline and 6 th month of injection. Both groups were compared by means of effi cieny. Results: Group 1 received single dose intravitreal dexamethasone implant and group 2 received mean 2.38±0.87 ranibizumab injections. Mean BCVA at baseline and month 6 was 1.0828±0.60419 and 0.7566±0.53714 logarithm of the minimum angle of resolution (logMAR) in group 1; 0.9891±0.50477 and 0.5781±0.41241 logMAR in group 2, respectively. Mean CMT at baseline and month 6 was 516.48±145.890 ?m and 428.69±148.497 ?m in group 1; 535.78±106.653 ?m and 358.94±115.860 ?m in group 2, respectively. There was an increase in BCVA and reduction in CMT in both groups at month 6 (p<0.05). But CMT in group 2 was signifi cantly less than group1 (p<0.05). Conclusion: Both intravitreal dexamethasone implant and ranibizumab injection effi cacy was found to be similar in the treatment of macular edema secondary to branch retinal vein occlusion. However, at month 6, ranibizumab appeared to have a greater effect on central macular thickness reduction compared to intravitreal dexamethasone implant.

Özet

Amaç: Retina ven dal tıkanıklıklarına (RVDT) bağlı makula ödemi tedavisinde intravitreal deksametazon implantı ve ranibizumab enjeksiyonunun 6. aydaki etkinliğini karşılaştırmak.Gereç ve Yöntem: Retina ven dal tıkanıklığına bağlı makula ödemi gelişen 61 hastanın gözü geriye dönük olarak incelendi. Yirmi dokuz (grup 1) hastaya 0.7 mg tek doz intravitreal deksametazon implantı ve 32 hastaya (grup 2) pro re nata (PRN) olarak 0.5 mg ranibizumab enjeksiyonu yapıldı. Enjeksiyon öncesi ve sonrası 6. aydaki en iyi düzeltilmiş görme keskinlikleri (EİDGK) ve santral makula kalınlıkları (SMK) kaydedildi. Her iki grup etkinlik açısından karşılaştırıldı. Bulgular: Grup 1' e tek doz deksametazon implant, grup 2' ye ortalama 2.38±0.87 ranibizumab enjeksiyonu yapıldı. Grup 1' in uygulama öncesi ve 6. ay ortalama EİDGK sırasıyla 1.0828±0.60419 ve 0.7566±0.53714 logarithm of the minimum angle of resolution (logMAR), grup 2' nin ise 0.9891±0.50477 ve 0.5781±0.41241 logMAR idi. Ortalama SMK uygulama öncesi ve 6. ayda grup 1' de 516.48±145.890 ?m ve 428.69±148.497 ?m, grup 2' de 535.78±106.653 ?m ve 358.94±115.860 ?m idi. Altıncı ayda her iki grupta EİDGK artışı ve SMK da azalma izlendi (p<0.05). Ancak grup 2' nin SMK 'sı grup 1' den anlamlı olarak düşük bulundu (p<0.05). Sonuç: Retina ven dal tıkanıklığına bağlı makula ödemi tedavisinde intravitreal deksametazon implant ve ranibizumab enjeksiyonunun etkinlikleri benzer bulundu. Ancak 6. ayda ranibizumabın SMK'daki azalma üzerine etkisinin deksametazon implantına göre daha fazla olduğu gözlendi.

🔖

Cite This Article

TÜRKSEVEN, E. K., YENEREL, N. M., ŞENGÜL, E. A., İMAMOĞLU, S., ERÇALIK, N. Y., SEVİM, M. Ş., BARDAK, H. (2017). Comparison of The Effi ciency of Intravitreal Dexamethasone Implant and Ranibizumab in The Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion: 6 Months Results. Retina-Vitreus, Cilt: 26 - Sayı: 2, 127–132. https://ajindex.com/articles/304896

References (14)

  1. Klein R, Klein BE, Moss SE, et al. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000;98:133-141
  2. Rehak J, Rehak M: Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 2008;33(2):111-31
  3. BVOs: Argon laser photocoagulation for macula edema in branch retinal vein occlusion. The branch retinal vein occlusion study group. Am J Ophthalmol 1984;98(3):271-282
  4. Ehlers JP, Fekrat S. Retinal vein occlusion: beyond the acute event. Surv Ophthalmol 2011;56(4):281-99
  5. Kadayıfçılar S. Retina ven tıkanıklıklarına bağlı maküla ödeminde anti-VEGF tedavisi. Turkiye Klinikleri J Ophthalmol-Special Topics 2013;6(1):127-31
  6. Feltgen N, Pielen A, Hansen L, et al. Intravitreale Medikamenteneingabe bei retinalem Venenverschluss-pathophysiologische Mechanismen und angewandte Substanzen. Klin Monatsbl Augenheilkd 2010;227(9):681-93
  7. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion-six month primary end point results of a phase III study. Ophthalmology 2010;117(6):1102-12.e1
  8. Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011;118:2453-60
  9. Kim M, Yu SY, Kim ES, et al. Intravitreal Ranibizumab for macular edema secondary to retinal vein occlusion. Ophthalmologica 2012;227:132-138
  10. Pece A, Isola V, Piermarocchi S: Effi cacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up. Br J Ophthalmol 2011; 95:56-68
  11. Jonas J.B., Akkoyun I, Kamppeter B, et al. Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye 2005;19:65-71
  12. Augustin AJ, Holz FG, Haritoglou C, et al. Retrospective, observational study in patients receiving a dexamethasone ıntravitreal implant 0.7 mg for macular edema secondary to retinal vein occlusion. Ophthalmologica 2015;233:18-26
  13. Joshi L, Yaganti S, Gemenetzi M, et al. Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using repeat injections as-needed. Br J Ophthalmol 2013;97:1040-4
  14. Queques L, Queques G, Lattanzio R, et al. Repeated intravitreal dexamethasone implant (Ozurdex®) for retinal vein occlusion. Ophthalmologica 2013;229:21-5